Parameters | Total | Luminal A | Luminal B | HER2 | TNBC | P-value |
---|---|---|---|---|---|---|
(N= 740) (%) | (n= 298) (%) | (n= 166) (%) | (n= 69) (%) | (n= 207) (%) | ||
Age (years, mean ± SD) | 49.7 ± 11.0 | 50.6 ± 10.5 | 48.5 ± 10.1 | 52.8 ± 9.8 | 48.4 ± 12.4 | 0.007 |
Histologic grade | Â | Â | Â | Â | Â | <0.001 |
 I | 118 (15.9) | 90 (30.2) | 18 (10.8) | 1 (1.4) | 9 (4.3) |  |
 II | 373 (50.4) | 180 (60.4) | 90 (54.2) | 35 (50.7) | 68 (32.9) |  |
 III | 249 (33.6) | 28 (9.4) | 58 (34.9) | 33 (47.8) | 130 (62.8) |  |
Tumor stage | Â | Â | Â | Â | Â | 0.002 |
 T1 | 358 (48.4) | 166 (55.7) | 86 (51.8) | 31 (44.9) | 75 (36.2) |  |
 T2 | 367 (49.6) | 125 (41.9) | 78 (47.0) | 37 (53.6) | 127 (61.4) |  |
 T3 | 15 (2.0) | 7 (2.3) | 2 (1.2) | 1 (1.4) | 5 (2.4) |  |
Nodal stage | Â | Â | Â | Â | Â | 0.041 |
 N0 | 436 (58.9) | 168 (56.4) | 91 (54.8) | 42 (60.9) | 135 (65.2) |  |
 N1 | 200 (27.0) | 90 (30.2) | 43 (25.9) | 13 (18.8) | 54 (26.1) |  |
 N2 | 66 (8.9) | 27 (9.1) | 17 (18.5) | 10 (14.5) | 12 (5.8) |  |
 N3 | 38 (5.1) | 13 (4.4) | 15 (9.0) | 4 (5.8) | 6 (2.9) |  |
Estrogen receptor status | Â | Â | Â | Â | Â | <0.001 |
 Negative | 286 (38.6) | 5 (1.7) | 5 (3.0) | 69 (100.0) | 207 (100.0) |  |
 Positive | 454 (61.4) | 293 (98.3) | 161 (97.0) | 0 (0.0) | 0 (0.0) |  |
Progesterone receptor status | Â | Â | Â | Â | Â | <0.001 |
 Negative | 371 (50.1) | 50 (16.8) | 46 (27.7) | 69 (100.0) | 207 (100.0) |  |
 Positive | 369 (49.9) | 248 (83.2) | 120 (72.3) | 0 (0.0) | 0 (0.0) |  |
HER2 status | Â | Â | Â | Â | Â | <0.001 |
 0 | 290 (39.2) | 108 (36.2) | 23 (13.9) | 0 (0.0) | 159 (76.8) |  |
 1+ | 186 (25.1) | 118 (39.6) | 33 (20.0) | 0 (0.0) | 35 (16.9) |  |
 2+ | 142 (19.2) | 72 (24.2) | 41 (24.7) | 16 (23.2) | 13 (6.3) |  |
 3+ | 122 (16.5) | 0 (0.0) | 69 (41.6) | 53 (76.8) | 0 (0.0) |  |
Ki-67 LI (%, mean ± SD) | 18.1 ± 19.2 | 4.7 ± 3.7 | 19.7 ± 12.7 | 19.5 ± 12.5 | 35.6 ± 23.7 | <0.001 |
Tumor recurrence | 69 (9.3) | 15 (5.0) | 12 (7.2) | 11 (15.9) | 31 (15.0) | <0.001 |
Patient’s death | 67 (9.1) | 14 (4.7) | 11 (6.6) | 12 (17.4) | 30 (14.5) | <0.001 |
Duration of clinical follow-up (months, mean ± SD) | 70.2 ± 31.7 | 72.7 ± 30.0 | 70.3 ± 30.3 | 67.1 ± 35.8 | 67.8 ± 33.8 | 0.291 |